在患有和没有壮成长症的受试者中,口服葡萄糖负载后异常增加GH
F Ceccato1,2, C K Vedolin1,2, G Voltan1,2
1Department of Medicine DIMED, University of Padova, Padua, Italy.
Journal of endocrinological investigation
|June 21, 2023
概括
在葡萄糖负载后发生矛盾的生长激素 (GH) 升高,定义为90分钟内20%的增加,在壮症中很常见. 这种反应,也在一些高IGF-1的非血性个体中观察到,可能表明疾病的早期阶段.
科学领域:
- 内分泌学 在内分泌学.
- 代谢障碍 代谢障碍 代谢障碍
- 激素调节 激素调节 激素调节
背景情况:
- 在葡萄糖负载 (GH-Par) 后发生矛盾的生长激素 (GH) 升高,约有三分之一的壮病患者出现这种情况.
- 精确的定义和GH-Par的含义需要进一步调查.
研究的目的:
- 为了评估和非的受试者的GH档案.
- 为了完善GH-Par. 的定义.
- 为了确定与壮症中GH-Par相关的临床特征.
主要方法:
- 观察性病例控制研究.
- 队列包括60名病患者和两个对照组 (高IGF-1的非病患者,n=116;正常IGF-1的非病患者,n=55).
- 在葡萄糖负载后180分钟内评估GH,胰岛素和葡萄糖水平.
主要成果:
- 在90分钟内将GH-Par定义修改为≥120%的GH峰值显示,巨 (42%) 与对照 (16%和7%,p<0.001) 相比,患病率更高.
- 患有GH-Par的阿克罗美加患者表现出更高的葡萄糖峰值,更慢的葡萄糖下降,增加的葡萄糖暴露,以及更高的糖尿病患病率.
- 在非GH-Par患者中观察到晚期GH反弹.
结论:
- GH-Par可以定义为在葡萄糖挑战后90分钟内20%的GH增加.
- GH-Par在壮症中很常见,并且与葡萄糖代谢异常有关.
- 在一些高IGF-1的非瘤患者中,GH-Par的存在表明它在早期瘤巨症中的潜在作用.
相关概念视频
Hypoglycemia and Glucagon
306
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
306
Hormones Regulating Blood Glucose
3.6K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.6K
Glucagon-like Receptor Agonists
366
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
366
Glucose Homeostasis: Regulation of Blood Glucose
1.8K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
1.8K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
210
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
210
Oral Hypoglycemic Agents: Biguanides and Glitazones
240
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
240


